Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In a phase 2 clinical trial, an inhibitor of the KCa2 potassium channel, which conducts a repolarizing current in the heart, met the primary endpoint of promoting cardioversion from atrial fibrillation to sinus rhythm within 90 minutes of drug administration.
Evidence supports the use of primary HPV testing to accelerate the global elimination of cervical cancer, but such recommendations must be viewed in the context of the fragile healthcare systems and complex implementation challenges in low-income and lower-middle income countries.
Resilience for future pandemics requires increased research and development, sustained vaccine manufacturing capabilities and global public–private collaboration.
A modelled evaluation of screening and treatment strategies for prevention of cervical cancer in 78 low- and lower-middle-income countries provides evidence to support the World Health Organization’s recommendation of primary HPV testing for women in the general population.
The authors discuss how screening strategies, treatment approaches and precision oncology are evolving in China and outline trends and priorities in the drug development and regulatory landscape.
A model evaluating cervical screening, triage and treatment strategies to prevent cervical cancer in women living with HIV in Tanzania provides evidence to support the World Health Organization’s recommendation of primary HPV testing starting at age 25 years with 3–5-year regular screening intervals.
A meta-analysis using the burden of proof risk function identified consistent evidence supporting harmful associations between the exposure to intimate partner violence against women and childhood sexual abuse on health outcomes.
In an ongoing phase 1/2 trial, mosunetuzumab, a CD20xCD3 bispecific antibody, plus polatuzumab vedotin, an anti-CD79B antibody–drug conjugate, had an overall response rate of 59.2%, supporting the potential of this combination for second-line treatment of patients with transplant-ineligible or CAR-T-cell-ineligible relapsed or refractory large B cell lymphoma.
In a large single-arm phase 2 trial, the anti-PD-1 inhibitor tislelizumab combined with the next-generation BTK inhibitor zanubrutinib had an overall response rate of 58.3% and was well tolerated in patients with Richter’s transformation.
Glial cells influence brain function and disease progression. This study identifies signals that elicit hemorrhage-specific glia plasticity, including proliferation and the acquisition of neural stem cell properties. It thereby sets a foundation for aligning glia reactivity with disease progression and for attempting to use this endogenous stem cell pool for brain repair.
Research participants often do not represent the target population for treatment. Systematic exclusion of particular groups limits the generalizability of research and perpetuates health inequalities. The REP-EQUITY toolkit guides representative and equitable inclusion in research. Its use may promote trust between communities and research institutions and improve the applicability of research findings.
Developed through systematic review and expert consensus, the REP-EQUITY toolkit provides a seven-step guide for investigators to facilitate representative and equitable recruitment into clinical research studies.
Nature Medicine asks leading researchers to name their top clinical trial for 2024, from base editing and a vaccine against HIV to artificial intelligence tools for lung cancer and patient triage.
A multi-ancestry genome-wide association study of problematic alcohol use in one million individuals identified 110 risk variants and shows that multi-ancestry polygenic scores improve risk prediction compared with single-ancestry scores
A validated biomarker risk score based on the expression of 34 genes improves risk stratification of patients with meningioma, including prediction of post-operative radiotherapy benefit.
In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an encouraging overall response rate of 62.5% in patients with KRAS G12C-positive colorectal cancer.